Login to Your Account

Sanofi's HIV Vaccine Positive, But Historical Efficacy 'Modest'

By Donna Young

Friday, September 25, 2009
WASHINGTON - A U.S.-funded, Thailand-run, 16,000-patient Phase III study of Sanofi-Aventis Group SA's ALVAC HIV and VaxGen Inc.'s AIDSVAX B/E found that the prime-boost investigational vaccine regimen cut HIV infections by 31.2 percent - the first time an HIV vaccine candidate successfully reduced the risk of HIV infection in humans. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription